Net income
-27 million USD
2022-07-01 – 2023-06-30
Fundies. English
Apexigen, Inc.
EDGAR19 filing records in this dataset, filed from 2020-08-14 to 2023-08-25. Reported financial figures are available; chart coverage varies by period.
Short annual reporting periods
These figures cover less than a full year. They are not annualized and are excluded from full-year trends and comparisons.
- Cash and cash equivalents
- 9.37 million USD Source
Exact value
9369000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 24.9 million shares Source
Exact value
24850082 shares
Reported share-count change
1,375.22% · 23.2 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2023-08-25.
Financial data available through: 2022-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 2 of 11 periods available· newest 2022-12-31
- Net income: 2 of 11 periods available· newest 2022-12-31
- Operating cash flow: 2 of 11 periods available· newest 2022-12-31
- Capital expenditure: 2 of 11 periods available· newest 2022-12-31
- Total assets: 2 of 11 periods available· newest 2022-12-31
- Total liabilities: 2 of 11 periods available· newest 2022-12-31
- Current assets: 2 of 11 periods available· newest 2022-12-31
- Current liabilities: 2 of 11 periods available· newest 2022-12-31
- Cash and cash equivalents: 2 of 11 periods available· newest 2022-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 2 of 11 periods available· newest 2022-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 3.15 millionPrior period
−USD 28.92 million
–
Current period
−USD 32.07 million
–
Exact inputs and evidence
-32069000 − -28916000 = -3153000 USD
-28916000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source-32069000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 6.79 millionPrior period
−USD 23.9 million
–
Current period
−USD 30.69 million
–
Exact inputs and evidence
-30693000 − -23902000 = -6791000 USD
-23902000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source-30693000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+5.6%Prior period
USD 54,000
–
Current period
USD 57,000
–
Exact inputs and evidence
57000 − 54000 = 3000 USD
54000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source57000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2021 2021-01-01 – 2021-12-31 | −USD 28.92 million Exact valueExact value: -28916000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 23.9 million Exact valueExact value: -23902000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 54,000 Exact valueExact value: 54000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 23.96 million Calculation and evidence-23902000 − 54000 USD Exact free cash flow: -23956000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 32.07 million Exact valueExact value: -32069000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 30.69 million Exact valueExact value: -30693000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 57,000 Exact valueExact value: 57000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 30.75 million Calculation and evidence-30693000 − 57000 USD Exact free cash flow: -30750000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
19 filings · 579 latest values · 579 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001814140, 1814140, edgar:1814140
Also known as Apexigen, Inc., BROOKLINE CAPITAL ACQUISITION CORP., Brookline Capital Acquisition Corp.